Navigation Links
PneumRx, Inc. Announces CE Mark Approval for Its RePneu® Lung Volume Reduction Coil (LVRC™) System

MOUNTAIN VIEW, Calif., Oct. 13 /PRNewswire/ -- PneumRx, Inc. (, a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has received CE Mark approval for its RePneu Lung Volume Reduction Coil (LVRC) System to treat the later stages of emphysema.  

The RePneu LVRC System is a minimally invasive device intended to improve lung function in emphysema patients by brochoscopically implanting Nitinol coils into the lungs to compress damaged tissue (lung volume reduction) and restore elastic recoil to the healthier lung tissue.  This treatment offers a minimally invasive alternative to lung volume reduction surgery, and works independently of collateral ventilation.  

The CE mark approval enables PneumRx to move forward with commercialization in Europe and other select markets.  PneumRx intends to launch its RePneu LVRC System in Europe in the last quarter of 2010.  PneumRx plans to continue its ongoing partnership with physicians through training and by offering novel products for the diagnosis and treatment of lung disease.

"We are thrilled to have achieved this important milestone, and look forward to introducing our RePneu LVRC to the European market to help improve the lives of so many people who are suffering from emphysema and have few other viable treatment options," said Erin McGurk, President and CEO of PneumRx, Inc.  "We are extremely pleased with the significant improvements in pulmonary function tests, exercise tolerance, and quality of life experienced by our clinical trial patients, and expect to bring these same benefits to a broader population of emphysema patients with the commercialization of the RePneu LVRC System in Europe."

About PneumRx, Inc.

PneumRx, Inc. is a rapidly growing medical device company focused on the development and commercialization of innovative products to treat emphysema using minimally-invasive techniques.  It is a privately held company located in Mountain View, California.

SOURCE PneumRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:10/13/2015)... -- Families across the country have filed product ... pharmaceutical company,s blockbuster anti-nausea drug Zofran and congenital ... their fraudulent misrepresentations to prescribing physicians about the ...   Due to the large number of Zofran birth ... Panel on Multidistrict Litigation (JPML) has ordered that ...
(Date:10/13/2015)... LAS VEGAS , Oct. 13, 2015 ... field of vascular medicine and intervention through education and ... its annual conference,  VIVA 2015 . Sixteen trial results, ... be released for the first time on Monday and ... Vegas. --> --> ...
(Date:10/13/2015)... , Oct. 13, 2015   Generational Equity , ... businesses, is pleased to announce the acquisition of its ... Largo, Florida , by Meridian Biomedical, ... September 11, 2015. Florida ... --> Florida . To learn more, ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Commitment to Cure last night at the Mandarin Oriental in New York City. ...
(Date:10/13/2015)... ... 13, 2015 , ... Wimbledon Health Partners , the ... as well as pioneering the way for high schools, colleges and universities to ... Levitt as Chief Financial Officer. Levitt brings over 20 years of financial experience ...
(Date:10/13/2015)... ... October 13, 2015 , ... The added calories and sugar in ... So what is a parent to do? Registered dietitians from Retrofit , the ... this time of year. , “Halloween is a high-calorie holiday,” said Dara Aronow, ...
(Date:10/13/2015)... ... October 13, 2015 , ... The American Institutes for Research ... health staff caring for students who have experienced sexual assault and other trauma. The ... House during the Violence Against Women Act's 21st anniversary. , AIR ...
(Date:10/13/2015)... ... 2015 , ... CURE Media Group, the nation’s leading digital ... with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) to expand education and ... physicians. , “Waldenstrom’s Macroglobulinemia is a so-called ‘orphan disease’ that typically does ...
Breaking Medicine News(10 mins):